MDMiquel Duran-Frigola

Miquel Duran-Frigola

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miquel Duran-Frigola has a total of 233 co-authors. Here are the top co-authors by number of shared publications:

  • Patrick Aloy

    Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain

    18 shared publications
  • Gemma Turon

    9 shared publications
  • Martino Bertoni

    Joint IRB-BSC-CRG Programme in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain

    9 shared publications
  • Eduardo Pauls

    Joint IRB-BSC-CRG Programme in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain

    8 shared publications
  • Oriol Guitart-Pla

    Joint IRB-BSC-CRG Programme in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain

    8 shared publications
  • Gemma Turon

    Ersilia Open Source Initiative

    7 shared publications

Latest Publications

  • Open Access

    Bridging the AI Divide in Drug Discovery: Practical Lessons from Capacity Strengthening in Africa

    by Jason Hlozek, Miquel Duran-Frigola, Nicola Elliott-Wong, Rudolf Stander, Susan Winks, Gemma Turon, Kelly Chibale

    Artificial Intelligence (AI) has become an integral part of drug discovery in high-income countries. However, these advances have yet to be broadly adopted by research ecosystems in many low- and middle-income countries in Africa, where understudied infectious diseases, compounded by a growing noncommunicable disease burden, cause millions of deaths each year. Given adequate support and appropriate models AI could play a transformative role in under-resourced biomedical research ecosystems in Africa, democratizing drug discovery research. There is an urgent need to invest in building the critical infrastructure, tools, and capacity required. To drive this agenda forward, Ersilia, the H3D Centre, and H3D Foundation with support from the AI2050 program at Schmidt Sciences hosted a series of in-person and online workshops in Africa to grow the AI skills base for medicinal chemistry and enable adoption across regional research hubs. In this perspective article, we discuss the lessons learnt from this program, the fit-for-purpose open-source tools developed, and key considerations for future initiatives.


  • Open Access

    Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa

    by Gemma Turon, Mwila Mulubwa, Anna Montaner, Mathew Njoroge, Kelly Chibale, Miquel Duran-Frigola

    Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Our pipeline couples machine learning and artificial intelligence with physiologically-based pharmacokinetic (PBPK) and non-linear mixed effects (NLME) modelling to hypothesize which pharmacogenes could be of potential clinical interest, and which dose adjustments could be made to provide better treatment outcomes for African populations. Drug-gene pairs are first ranked with the latest knowledge embedding techniques, based on public structural and bioactivity data for drugs and genes, followed by a large language model-based refinement. Selected genes are then evaluated for their sensitivity in PBPK analysis, and relevant variants subsequently inspected with NLME for dose optimization. The analysis is focused on genes with potential clinical relevance in Africa. We delve deeper into malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective.


  • Top Cited Papers
    Open Access

    Learning and actioning general principles of cancer cell drug sensitivity

    by Francesco Carli, Pierluigi Di Chiaro, Mariangela Morelli, Chakit Arora, Luisa Bisceglia, Natalia De Oliveira Rosa, Alice Cortesi, Sara Franceschi, Francesca Lessi, Anna Luisa Di Stefano, et al.

    High-throughput screening of drug sensitivity of cancer cell lines (CCLs) holds the potential to unlock anti-tumor therapies. In this study, we leverage such datasets to predict drug response using cell line transcriptomics, focusing on models’ interpretability and deployment on patients’ data. We use large language models (LLMs) to match drug to mechanisms of action (MOA)-related pathways. Genes crucial for prediction are enriched in drug-MOAs, suggesting that our models learn the molecular determinants of response. Furthermore, by using only LLM-curated, MOA-genes, we enhance the predictive accuracy of our models. To enhance translatability, we align RNAseq data from CCLs, used for training, to those from patient samples, used for inference. We validated our approach on TCGA samples, where patients’ best scoring drugs match those prescribed for their cancer type. We further predict and experimentally validate effective drugs for the patients of two highly lethal solid tumors, i.e., pancreatic cancer and glioblastoma.


  • Open Access

    The Chemical Space Spanned by Manually Curated Datasets of Natural and Synthetic Compounds with Activities against SARS‐CoV‐2

    by Jude Y. Betow, Gemma Turon, Clovis S. Metuge, Simeon Akame, Vanessa A. Shu, Oyere T. Ebob, Miquel Duran‐Frigola, Fidele Ntie‐Kang

    Diseases caused by viruses are challenging to contain, as their outbreak and spread could be very sudden, compounded by rapid mutations, making the development of drugs and vaccines a continued endeavour that requires fast discovery and preparedness. Targeting viral infections with small molecules remains one of the treatment options to reduce transmission and the disease burden. A lesson learned from the recent coronavirus disease (COVID‐19) is to collect ready‐to‐screen small molecule libraries in preparation for the next viral outbreak, and potentially find a clinical candidate before it becomes a pandemic. Public availability of diverse compound libraries, well annotated in terms of chemical structures and scaffolds, modes of action, and bioactivities are, therefore, crucial to ensure the participation of academic laboratories in these screening efforts, especially in resource‐limited settings where synthesis, testing and computing capacity are scarce. Here, we demonstrate a low‐resource approach to populate the chemical space of naturally occurring and synthetic small molecules that have shown in vitro and/or in vivo activities against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its target proteins. We have manually curated two datasets of small molecules (naturally occurring and synthetically derived) by reading and collecting (hand‐curating) the published literature. Information from the literature reveals that a majority of the reported SARS‐CoV‐2 compounds act by inhibiting the main protease, while 25% of the compounds currently have no known target. Scaffold analysis and principal component analysis revealed that the most common scaffolds in the datasets are quite distinct. We then expanded the initially manually curated dataset of over 1200 compounds via an ultra‐large scale 2D and 3D similarity search, obtaining an expanded collection of over 150 k purchasable compounds. The spanned chemical space significantly extends beyond that of a commercially available coronavirus library of more than 20 k small molecules and constitutes a good starting collection for virtual screening campaigns given its manageable size and proximity to hand‐curated compounds.


  • Open Access

    AI coupled to pharmacometric modelling to tailor malaria and tuberculosis treatment in Africa

    by Gemma Turon, Mwila Mulubwa, Anna Montaner, Mathew Njoroge, Kelly Chibale, Miquel Duran-Frigola

    Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Furthermore, we delve deeper into the analysis of malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective. Our pipeline leverages artificial intelligence and the latest advances in knowledge embedding techniques to exploit currently available biomedical data and subsequently prioritise pharmacogenes for each drug. Predicted pharmacogenes are then incorporated into pharmacometric modelling to hypothesise which ones might be of clinical interest, and which dose adjustments could be made to provide better treatment outcomes for the African population.

  • Open Source Code Contributions to Global Health: The Case of Antimalarial Drug Discovery

    by Gemma Turon, Edwin Tse, Xin Qiu, Matthew Todd, Miquel Duran-Frigola

    The discovery of treatments for infectious diseases that affect the poorest countries has been stagnant for decades. As long as expected returns on investment remain low, pharmaceutical companies' lack of interest in this disease area must be compensated for with collaborative efforts from the public sector. New approaches to drug discovery, inspired by the "open source" philosophy prevalent in software development, offer a platform for experts from diverse backgrounds to contribute their skills, enhancing reproducibility, progress tracking, and public discussion. Here, we present the first efforts of Ersilia, an initiative focused on attracting data scientists into contributing to global health, toward meeting the goals of Open Source Malaria, a consortium of medicinal chemists investigating antimalarial compounds using a purely open science approach. We showcase the chemical space exploration of a set of triazolopyrazine compounds with potent antiplasmodial activity and discuss how open source practices can serve as a common ground to make drug discovery more inclusive and participative.


  • Top Cited Papers

    Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells

    by Fabian Offensperger, Gary Tin, Miquel Duran-Frigola, Elisa Hahn, Sarah Dobner, Christopher W. Am Ende, Joseph W. Strohbach, Andrea Rukavina, Vincenth Brennsteiner, Kevin Ogilvie, et al.

    Chemical modulation of proteins enables a mechanistic understanding of biology and represents the foundation of most therapeutics. However, despite decades of research, 80% of the human proteome lacks functional ligands. Chemical proteomics has advanced fragment-based ligand discovery toward cellular systems, but throughput limitations have stymied the scalable identification of fragment-protein interactions. We report proteome-wide maps of protein-binding propensity for 407 structurally diverse small-molecule fragments. We verified that identified interactions can be advanced to active chemical probes of E3 ubiquitin ligases, transporters, and kinases. Integrating machine learning binary classifiers further enabled interpretable predictions of fragment behavior in cells. The resulting resource of fragment-protein interactions and predictive models will help to elucidate principles of molecular recognition and expedite ligand discovery efforts for hitherto undrugged proteins.


  • AI can help to tailor drugs for Africa — but Africans should lead the way

    by Gemma Turon, Mathew Njoroge, Mwila Mulubwa, Miquel Duran-Frigola, Kelly Chibale